Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial
复制标题
DOI：
10.1002/ejhf.207
复制
发表时间：
2015-01-01
影响因子：
18.2
通讯作者：
O'Connor, Christopher M.
中科院分区：
文献类型：
--
作者：
Metra, Marco;Mentz, Robert J.;O'Connor, Christopher M.
目的
先前的心力衰竭（HF）试验表明，年龄影响患者特征和预后；然而，老年患者代表性不足限制了对这一人群的特征描述。标准预后变量在不同年龄组是否具有不同的效用尚不清楚。
方法与结果
PROTECT试验研究了2033例急性心力衰竭患者（中位年龄72岁），随机接受咯利普兰或安慰剂治疗。根据年龄的五分位数将患者分为五组：<59岁、60 - 68岁、69 - 74岁、75 - 79岁和≥80岁。对基线特征、用药情况和预后（30天死亡或心血管/肾脏住院，以及30天和180天死亡）进行了探究。在不同组以及特定年龄组中研究了基线特征对预后的预测效用。
AimsPrevious heart failure (HF) trials suggested that age influences patient characteristics and outcome; however, under-representation of elderly patients has limited characterization of this cohort. Whether standard prognostic variables have differential utility in various age groups is unclear.Methods and resultsThe PROTECT trial investigated 2033 patients (median age 72 years) with acute HF randomized to rolofylline or placebo. Patients were divided into five groups based on the quintiles of age: 59, 60-68, 69-74, 75-79, and 80years. Baseline characteristics, medications, and outcomes (30-day death or cardiovascular/renal hospitalization, and death at 30 and 180 days) were explored. The prognostic utility of baseline characteristics for outcomes was investigated in the different groups and in those aged